Print this page
-
A Phase I Study to Evaluate the Safety of Naltrexone and Propranolol in Combination with Standard of Care Ipilimumab and Nivolumab in Patients with Advanced Melanoma.
Protocol: 092302Principal Investigator:
- Sarah Weiss MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Melanoma, Skin -
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-Stage Triple-Negative Breast Cancer.
Protocol: 042304Principal Investigator:
- Mridula George (Rutgers University)
Applicable Disease Sites: Breast -
Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer.
Protocol: 032204Principal Investigator:
- Malcolm Mattes (New Jersey Medical School)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx
Larynx -
First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in
Participants with B-cell Malignancies
Protocol: 012321Principal Investigator:
- Joanna Rhodes MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 1/2, First in Human Study of DCC-3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations
Protocol: 052308Principal Investigator:
- Sanjay Goel (Rutgers University)
Applicable Disease Sites: Any Site -
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants with Advanced Malignancies
Protocol: 052310Principal Investigator:
- Sanjay Goel (Rutgers University)
Applicable Disease Sites: Any Site